Equities

Regenxbio Inc

Regenxbio Inc

Actions
  • Price (EUR)11.10
  • Today's Change-0.10 / -0.89%
  • Shares traded0.00
  • 1 Year change-33.53%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Regenxbio Inc had revenues fall -19.94% from 112.72m to 90.24m, though the company grew net income from a loss of 280.32m to a smaller loss of 263.49m.
Gross margin56.78%
Net profit margin-270.74%
Operating margin-279.37%
Return on assets-38.52%
Return on equity-63.94%
Return on investment-46.55%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Regenxbio Inc fell by 62.43m. However, Cash Flow from Investing totalled 190.94m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 218.41m for operations while cash used for financing totalled 34.97m.
Cash flow per share-4.87
Price/Cash flow per share--
Book value per share7.06
Tangible book value per share7.06
More ▼

Balance sheet in USDView more

Regenxbio Inc uses little or no debt in its capital structure.
Current ratio3.53
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.